207 related articles for article (PubMed ID: 31619389)
1. Brain Distributional Kinetics of a Novel MDM2 Inhibitor SAR405838: Implications for Use in Brain Tumor Therapy.
Kim M; Laramy JK; Gampa G; Parrish KE; Brundage R; Sarkaria JN; Elmquist WF
Drug Metab Dispos; 2019 Dec; 47(12):1403-1414. PubMed ID: 31619389
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier.
Kim M; Ma DJ; Calligaris D; Zhang S; Feathers RW; Vaubel RA; Meaux I; Mladek AC; Parrish KE; Jin F; Barriere C; Debussche L; Watters J; Tian S; Decker PA; Eckel-Passow JE; Kitange GJ; Johnson AJ; Parney IF; Anastasiadis PZ; Agar NYR; Elmquist WF; Sarkaria JN
Mol Cancer Ther; 2018 Sep; 17(9):1893-1901. PubMed ID: 29970480
[TBL] [Abstract][Full Text] [Related]
3. Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases.
Gampa G; Kim M; Cook-Rostie N; Laramy JK; Sarkaria JN; Paradiso L; DePalatis L; Elmquist WF
Drug Metab Dispos; 2018 May; 46(5):658-666. PubMed ID: 29437873
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases.
Mittapalli RK; Vaidhyanathan S; Dudek AZ; Elmquist WF
J Pharmacol Exp Ther; 2013 Mar; 344(3):655-64. PubMed ID: 23249624
[TBL] [Abstract][Full Text] [Related]
5. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032).
Mittapalli RK; Vaidhyanathan S; Sane R; Elmquist WF
J Pharmacol Exp Ther; 2012 Jul; 342(1):33-40. PubMed ID: 22454535
[TBL] [Abstract][Full Text] [Related]
6. SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression.
Wang S; Sun W; Zhao Y; McEachern D; Meaux I; Barrière C; Stuckey JA; Meagher JL; Bai L; Liu L; Hoffman-Luca CG; Lu J; Shangary S; Yu S; Bernard D; Aguilar A; Dos-Santos O; Besret L; Guerif S; Pannier P; Gorge-Bernat D; Debussche L
Cancer Res; 2014 Oct; 74(20):5855-65. PubMed ID: 25145672
[TBL] [Abstract][Full Text] [Related]
7. Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment.
Hoffman-Luca CG; Yang CY; Lu J; Ziazadeh D; McEachern D; Debussche L; Wang S
PLoS One; 2015; 10(6):e0128807. PubMed ID: 26070072
[TBL] [Abstract][Full Text] [Related]
8. Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.
Sane R; Agarwal S; Mittapalli RK; Elmquist WF
J Pharmacol Exp Ther; 2013 Apr; 345(1):111-24. PubMed ID: 23397054
[TBL] [Abstract][Full Text] [Related]
9. Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model.
Parrish KE; Pokorny J; Mittapalli RK; Bakken K; Sarkaria JN; Elmquist WF
J Pharmacol Exp Ther; 2015 Nov; 355(2):264-71. PubMed ID: 26354993
[TBL] [Abstract][Full Text] [Related]
10. Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma.
Lu J; Guan S; Zhao Y; Yu Y; Wang Y; Shi Y; Mao X; Yang KL; Sun W; Xu X; Yi JS; Yang T; Yang J; Nuchtern JG
Oncotarget; 2016 Dec; 7(50):82757-82769. PubMed ID: 27764791
[TBL] [Abstract][Full Text] [Related]
11. Role of Human Breast Cancer Related Protein versus P-Glycoprotein as an Efflux Transporter for Benzylpenicillin: Potential Importance at the Blood-Brain Barrier.
Li Y; Wu Q; Li C; Liu L; Du K; Shen J; Wu Y; Zhao X; Zhao M; Bao L; Gao J; Keep RF; Xiang J
PLoS One; 2016; 11(6):e0157576. PubMed ID: 27300692
[TBL] [Abstract][Full Text] [Related]
12. P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability.
Martínez-Chávez A; van Hoppe S; Rosing H; Lebre MC; Tibben M; Beijnen JH; Schinkel AH
Mol Pharm; 2019 Sep; 16(9):3842-3852. PubMed ID: 31329454
[TBL] [Abstract][Full Text] [Related]
13. Central Nervous System Distribution of the Ataxia-Telangiectasia Mutated Kinase Inhibitor AZD1390: Implications for the Treatment of Brain Tumors.
Talele S; Zhang W; Chen J; Gupta SK; Burgenske DM; Sarkaria JN; Elmquist WF
J Pharmacol Exp Ther; 2022 Oct; 383(1):91-102. PubMed ID: 36137710
[TBL] [Abstract][Full Text] [Related]
14. Characterization and Validation of Canine P-Glycoprotein-Deficient MDCK II Cell Lines for Efflux Substrate Screening.
Ye D; Harder A; Fang Z; Weinheimer M; Laplanche L; Mezler M
Pharm Res; 2020 Sep; 37(10):194. PubMed ID: 32918191
[TBL] [Abstract][Full Text] [Related]
15. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux.
Agarwal S; Sane R; Gallardo JL; Ohlfest JR; Elmquist WF
J Pharmacol Exp Ther; 2010 Jul; 334(1):147-55. PubMed ID: 20421331
[TBL] [Abstract][Full Text] [Related]
16. ABCB1 Attenuates the Brain Penetration of the PARP Inhibitor AZD2461.
de Gooijer MC; Buil LCM; Çitirikkaya CH; Hermans J; Beijnen JH; van Tellingen O
Mol Pharm; 2018 Nov; 15(11):5236-5243. PubMed ID: 30252484
[TBL] [Abstract][Full Text] [Related]
17. Prediction of Human Brain Penetration of P-glycoprotein and Breast Cancer Resistance Protein Substrates Using In Vitro Transporter Studies and Animal Models.
Feng B; Doran AC; Di L; West MA; Osgood SM; Mancuso JY; Shaffer CL; Tremaine L; Liras J
J Pharm Sci; 2018 Aug; 107(8):2225-2235. PubMed ID: 29608887
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699).
Durmus S; Sparidans RW; van Esch A; Wagenaar E; Beijnen JH; Schinkel AH
Pharm Res; 2015 Jan; 32(1):37-46. PubMed ID: 24962512
[TBL] [Abstract][Full Text] [Related]
19. Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases.
Vaidhyanathan S; Mittapalli RK; Sarkaria JN; Elmquist WF
Drug Metab Dispos; 2014 Aug; 42(8):1292-300. PubMed ID: 24875464
[TBL] [Abstract][Full Text] [Related]
20. Tetrahydrocannabinol and Its Major Metabolites Are Not (or Are Poor) Substrates or Inhibitors of Human P-Glycoprotein [ATP-Binding Cassette (ABC) B1] and Breast Cancer Resistance Protein (ABCG2).
Chen X; Unadkat JD; Mao Q
Drug Metab Dispos; 2021 Oct; 49(10):910-918. PubMed ID: 34326138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]